Education
About Us
Working with TipRanks
Follow Us
Verona Pharma Plc (VRNA)
NASDAQ:VRNA
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.04Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -1.29%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, driven by the successful launch and strong initial sales of O2VARE, significant prescriber adoption, and strategic global expansion efforts. However, increased costs and losses and some challenges with reimbursement are noted as areas of concern.Company Guidance
In the Verona Pharma call discussing their fourth quarter and full year 2024 financial results, significant progress was highlighted, particularly with the launch of O2VARE for COPD treatment. Key metrics included $36.6 million in net sales for Q4 and $42.3 million for the entire year. The launch saw strong uptake, with over 4,600 unique healthcare providers prescribing O2VARE, including 55% of their tier one providers. They observed growth in new patient starts and refills, indicating a positive reception. Financially, they reported a net loss of $33.8 million for Q4, with a $400 million cash reserve, and access to an additional $425 million. The company continues to expand globally, with O2VARE approved in Macau and ongoing regulatory and marketing authorization efforts in the EU and UK. Additionally, Verona Pharma is progressing with two Phase 2 clinical programs, further emphasizing their commitment to advancing COPD treatments.Successful Launch of O2VARE
In the first full quarter of commercial availability, net sales of O2VARE were $36.6 million in Q4 and $42.3 million for the full year 2024. The launch momentum is strong with more prescriptions dispensed in the first two months of Q1 2025 than in Q4 2024.
Positive Prescriber Adoption
Over 4,600 unique HCPs are prescribing O2VARE, including 55% of 2,500 tier one HCPs. Over 275 HCPs have prescribed O2VARE to more than 20 patients in their practice.
Global Expansion and Regulatory Advances
Nuance Pharma announced the approval of O2VARE in Macau and completed enrollment in its pivotal Phase 3 clinical trial in China. Preparations are underway for potential marketing authorization applications in the EU and UK.
Strong Financial Position
Verona Pharma ended 2024 with $400 million in cash and equivalents, with access to up to $425 million of additional capital through the Oak Creek facility.
Pipeline Progress
Completed Phase 2 clinical trial with glycopyrrolate ALAMA and plans to initiate a Phase 2b trial evaluating a fixed-dose combination of ensifentrine with glycopyrrolate in the second half of 2025.
---
VRNA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VRNA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $63.52 | $67.12 | +5.67% |
| Nov 04, 2024 | $34.98 | $38.15 | +9.06% |
| Aug 08, 2024 | $19.53 | $21.60 | +10.60% |
| May 09, 2024 | $14.88 | $14.75 | -0.87% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Verona Pharma Plc (VRNA) report earnings?
Verona Pharma Plc (VRNA) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Verona Pharma Plc (VRNA) earnings time?
Verona Pharma Plc (VRNA) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VRNA EPS forecast?
VRNA EPS forecast for the fiscal quarter 2025 (Q1) is -0.07.
---